Literature DB >> 24510836

DNA electroporation of multi-agent vaccines conferring protection against select agent challenge: TriGrid delivery system.

Andrea M Keane-Myers1, Matt Bell, Drew Hannaman, Mark Albrecht.   

Abstract

Effective multi-agent/multivalent vaccines that confer protection against more than one disease are highly desirable to the patient and to health-care professionals. Electroporation of DNA vaccines, whereby tissues injected with DNA are subjected to localized electrical currents, is an ideal platform technology that achieves protective immune responses to multivalent vaccination. Here, we describe an electroporation-based immunization technique capable of administering a cocktail of DNA vaccinations in vivo. Immune response measurements, including protection from pathogen challenge and induction of antigen-specific antibody responses and cell-mediated immune responses, are also discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24510836     DOI: 10.1007/978-1-4614-9632-8_29

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  4 in total

Review 1.  Electroporation for therapeutic DNA vaccination in patients.

Authors:  Matti Sällberg; Lars Frelin; Gustaf Ahlén; Margaret Sällberg-Chen
Journal:  Med Microbiol Immunol       Date:  2014-12-23       Impact factor: 3.402

2.  Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens.

Authors:  Helen Cho; Joe Binder; Risini Weeratna; Michael Dermyer; Stanley Dai; Antionio Boccia; Wei Li; Shangjin Li; Karin Jooss; James Merson; Robert E Hollingsworth
Journal:  Cancer Immunol Immunother       Date:  2022-07-13       Impact factor: 6.630

3.  Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.

Authors:  Hannah Mary Cheeseman; Suzanne Day; Leon Robert McFarlane; Sue Fleck; Aleisha Miller; Tom Cole; Nelson Sousa-Santos; Alethea Cope; Deniz Cizmeci; Monica Tolazzi; Edith Hwekwete; Drew Hannaman; Sven Kratochvil; Paul Francis McKay; Amy W Chung; Stephen J Kent; Adrian Cook; Gabriella Scarlatti; Sonya Abraham; Behazine Combadiere; Sheena McCormack; David John Lewis; Robin John Shattock
Journal:  Hum Gene Ther       Date:  2018-09       Impact factor: 5.695

4.  Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.

Authors:  G Haidari; A Cope; A Miller; S Venables; C Yan; H Ridgers; K Reijonen; D Hannaman; A Spentzou; P Hayes; G Bouliotis; A Vogt; S Joseph; B Combadiere; S McCormack; R J Shattock
Journal:  Sci Rep       Date:  2017-10-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.